| Trial ID: | L7182 |
| Source ID: | NCT04864977
|
| Associated Drug: |
Basal Insulin
|
| Title: |
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Type 2 Diabetes Treated With Insulin
|
| Interventions: |
DRUG: Basal Insulin
|
| Outcome Measures: |
Primary: Percentage of Participants with Type 2 Diabetes Who Achieve Nadir Glucose in Range 70-125 milligram/deciliter (mg/dL), Percentage of participants with type 2 diabetes who achieve nadir glucose in range (70-125 mg/dl) over 15 consecutive minutes for ≥70% of days (typically 10 days) (last 14 days of active treatment), Week 12 | Secondary: Percentage of Participants with Hemoglobin A1c (HbA1c) at target (<7.0%), Week 12|Percentage of Participants with time in range (TIR) 70-180 mg/dl ≥70%, Week 12|Percentage of Participants who successfully use Continuous Glucose Monitoring (CGM), Week 12
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-08-16
|
| Completion Date: |
2022-06-06
|
| Results First Posted: |
|
| Last Update Posted: |
2021-08-24
|
| Locations: |
Boston Medical Center, Boston, Massachusetts, 02118, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04864977
|
